Author

Ryuta Niikura

The University of Tokyo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

Daiju KitagawaiD· 2 shared Masamitsu FukuyamaiD· 2 shared Shohei YamamotoiD· 2 shared Susumu GoyamaiD· 2 shared Takumi ChineniD· 2 shared Akinori KanaiiD· 1 shared Goro TeraiiD· 1 shared Hideko Uga· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Daiju KitagawaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 14, 2026

Pathway-Centric Integration of CRISPR Fitness with Molecular Features Draws Cancer State Maps

Tamaki Hagiwara, Kei Ito, Kanako Kuroki…·Daiju Kitagawa

StateMap integrates CRISPR fitness and gene expression data to map cancer pathway states, identifying therapeutic vulnerabilities in the Hippo pathway.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 27, 2024

Latent mitotic vulnerability of AML cells induced by therapeutic agents

Ryuta Niikura, Tomohiro Yabushita, Shohei Yamamoto…·Daiju Kitagawa

This study identifies mitotic vulnerabilities in AML cells induced by therapeutic agents, showing increased cytotoxicity during mitosis compared to S/G2 phase arrest.

DOI 10.1101/2024.06.27.600939

humanbulk RNA-seq

𝕏 PostBluesky